Patents Represented by Attorney, Agent or Law Firm Steve M. Odre
-
Patent number: 6541033Abstract: The present invention relates generally to the development of pharmaceutical compositions which provide for sustained release of biologically active polypeptides. More specifically, the invention relates to the use of thermosensitive, biodegradable hydrogels, consisting of a block copolymer of poly(d,l- or l-lactic acid)(PLA) or poly(lactide-co-glycolide)(PLGA) and polyethylene glycol (PEG), for the sustained delivery of biologically active agents, such as leptin.Type: GrantFiled: June 30, 1998Date of Patent: April 1, 2003Assignee: Amgen Inc.Inventor: Subodh Shah
-
Patent number: 6479250Abstract: Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.Type: GrantFiled: July 7, 2000Date of Patent: November 12, 2002Assignee: Amgen Inc.Inventors: Timothy D. Bartley, William J. Boyle, Gary M. Fox, Andrew A. Welcher, Ella Magal, Richard A. Lindberg, Vann P. Parker
-
Patent number: 6288030Abstract: The present invention relates to lyophilized formulations of Stem Cell Factor (SCF) with increased stability. The formulations of lyophilized SCF include amino acid buffers and sucrose. Methods of producing said formulations are also disclosed in the specification.Type: GrantFiled: December 22, 1993Date of Patent: September 11, 2001Assignee: Amgen Inc.Inventor: Susan I. Hershenson
-
Patent number: 6077689Abstract: Disclosed are methods for improving the solubility of a protein of interest produced recombinantly by expressing the protein of interest as a fusion protein with a member of the 14-3-3 family of proteins.Type: GrantFiled: December 24, 1997Date of Patent: June 20, 2000Assignee: Amgen Inc.Inventor: Marshall Davenport Snavely
-
Patent number: 6063903Abstract: Polypeptides which bind to one or more EPH-like receptors, particularly the HEK4 receptor, are described. The polypeptides are designated HEK4 binding proteins. Nucleic acids encoding HEK4 binding proteins, and expression vectors, host cells and processes for the production of the polypeptides are also described. The polypeptides are useful for modulating the growth and/or differentiation of a variety of tissues, including those from liver, kidney, lung, skin, digestive tract and nervous system and may be used to regenerate damaged or depleted tissue and to treat cancer or nervous system disorders.Type: GrantFiled: March 25, 1998Date of Patent: May 16, 2000Assignee: Amgen Inc.Inventors: Timothy D. Bartley, Gary M. Fox
-
Patent number: 6057124Abstract: Polypeptides which bind to one or more EPH-like receptors, particularly the HEK4 receptor, are described. The polypeptides are designated HEK4 binding proteins. Nucleic acids encoding HEK4 binding proteins, and expression vectors, host cells and processes for the production of the polypeptides are also described. The polypeptides are useful for modulating the growth and/or differentiation of a variety of tissues, including those from liver, kidney, lung, skin, digestive tract and nervous system and may be used to regenerate damaged or depleted tissue and to treat cancer or nervous system disorders.Type: GrantFiled: January 27, 1995Date of Patent: May 2, 2000Assignee: Amgen Inc.Inventors: Timothy D. Bartley, Gary M. Fox
-
Patent number: 6054294Abstract: Disclosed are nucleic acids encoding novel neurotrophic factors, designated NNT-1. Also disclosed are amino acid sequences for NNT-1 polypeptides, methods for preparing NNT-1 polypeptides, and other related aspects.Type: GrantFiled: December 12, 1997Date of Patent: April 25, 2000Assignee: Amgen Inc.Inventor: Ming-shi Chang
-
Patent number: 6015938Abstract: The present invention discloses a novel secreted polypeptide, termed Osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding Osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind Osteoprotegerin, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis.Type: GrantFiled: November 18, 1997Date of Patent: January 18, 2000Assignee: Amgen Inc.Inventors: William J. Boyle, David L. Lacey, Frank J. Calzone, Ming-Shi Chang
-
Patent number: 5981245Abstract: Four novel members of the EPH sub-family of receptor protein tyrosine kinases are disclosed. Nucleic acid sequences encoding receptor proteins, recombinant plasmids and host cells for expression, and methods of producing and using such receptors are also disclosed.Type: GrantFiled: May 24, 1995Date of Patent: November 9, 1999Assignee: Amgen Inc.Inventors: Gary M. Fox, Andrew A. Welcher, Shuqian Jing
-
Patent number: 5919911Abstract: The present invention relates to monoclonal antibodies specific for a cell receptor specific for human stem cell factor (hSCF) as well as pharmaceutical compositions containing such monoclonal antibodies and uses of such monoclonal antibodies.Type: GrantFiled: June 5, 1995Date of Patent: July 6, 1999Assignee: Board of Regents of the University of WashingtonInventors: Virginia C. Broudy, Nancy Lin
-
Patent number: 5906938Abstract: The present invention relates to monoclonal antibodies specific for a cell receptor specific for human stem cell factor (hSCF) as well as pharmaceutical compositions containing such monoclonal antibodies and uses of such monoclonal antibodies for the isolation and reconstitution of hematopoietic cells expressing the stem cell factor receptor.Type: GrantFiled: May 24, 1995Date of Patent: May 25, 1999Assignee: Board of Regents of the University of WashingtonInventors: Virginia C. Broudy, Nancy Lin
-
Patent number: 5885574Abstract: Antibodies and fragments thereof which activate an erythropoietin receptor and stimulate erythropoiesis are described. Also described are hybridoma cell lines which produce the antibodies and methods and compositions for the treatment of anemia.Type: GrantFiled: July 26, 1994Date of Patent: March 23, 1999Assignee: Amgen Inc.Inventor: Steven G. Elliott
-
Patent number: 5824303Abstract: Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.Type: GrantFiled: May 19, 1995Date of Patent: October 20, 1998Assignee: Amgen Inc.Inventors: Timothy D. Bartley, William J. Boyle, Gary M. Fox, Andrew A. Welcher, Ella Magal, Richard A. Lindberg, Vann P. Parker
-
Patent number: 5716934Abstract: Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.Type: GrantFiled: May 30, 1995Date of Patent: February 10, 1998Assignee: Amgen Inc.Inventors: Timothy D. Bartley, William J. Boyle, Vann P. Parker, Gary M. Fox, Andrew A. Welcher